Longevity Medicine, Functional Wellness & Anti-Aging Insights from HormoneSynergy®

The idea that Alzheimer’s is “Type 3 diabetes” has gained traction—but it’s not the full story. Here’s what’s true, what’s oversimplified, and how this fits into a longevity medicine perspective.

A recent large observational study suggests statins may be associated with lower Alzheimer’s risk, but the full story is more complex. Here’s what the data actually shows, what it does not prove, and how it fits into a longevity medicine perspective.

ApoB reflects the number of atherogenic particles in circulation. Understanding optimal ranges helps clarify cardiovascular risk beyond traditional cholesterol measurements.

Lp(a) levels are genetically determined, but knowing what is considered high can help clarify cardiovascular risk. Understanding Lp(a) thresholds is key to interpreting this often-overlooked marker.

ApoB and LDL-P both estimate atherogenic particle burden, but they are not identical. Understanding how they differ helps clarify cardiovascular risk beyond standard cholesterol panels.

LDL-C and LDL-P are related, but they are not the same. In some people, LDL cholesterol appears normal while LDL particle number remains elevated, creating a discordance that can underestimate cardiovascular risk.

“Anti-aging” may sound appealing, but it is often more marketing than medicine. At HormoneSynergy®, we believe in a more honest approach: longevity medicine focused on preventing, slowing, and sometimes helping reverse the common diseases and patterns associated with aging through earlier, more thoughtful care.

LDL particle number (LDL-P) provides a deeper look at cardiovascular risk by measuring the number of LDL particles, not just the cholesterol they carry. It can reveal hidden risk even when LDL-C appears normal.

Remnant cholesterol is one of the most overlooked markers in cardiometabolic risk. It may help explain why some people with “normal” LDL cholesterol still carry meaningful cardiovascular and metabolic risk.

The triglyceride-to-HDL ratio is one of the simplest ways to assess metabolic health and insulin resistance. Here’s what it means, why it matters, and how it fits into longevity medicine.

Many people are told their cholesterol is “normal,” yet still develop cardiovascular disease. This article explains why standard lipid panels can miss risk and how a longevity medicine approach looks deeper.

LDL cholesterol has been the standard marker for decades, but ApoB may provide a more accurate picture of cardiovascular risk. Here’s how they differ—and why it matters in longevity medicine.